Cited by 259Smoking Behavior and CessationTreatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.

Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent

Open access

Dwoskin, Linda P., Rauhut, Anthony S., King‐Pospisil, Kelley A., Bardo, Michael T.·2006·CNS Drug Reviews

DOI 10.1111/j.1527-3458.2006.00178.xPMC PMC6506196

Open this paper in CoChat — free account Open PDF

Abstract

Bupropion hydrochloride ((+/-)-2-tert-butylamino)-3'-chloropropiophenone x HCl) is a nonselective inhibitor of the dopamine transporter (DAT) and the norepinephrine transporter (NET) and is also an antagonist at neuronal nicotinic acetylcholine receptors (nAChRs). In animal models used commonly to screen for antidepressant activity, bupropion shows a positive response. Also using animal models, bupropion has been shown to attenuate nicotine-induced unconditioned behaviors, to share or enhance discriminative stimulus properties of nicotine and to have a complex effect on nicotine self-administration, i.e., low doses augmenting nicotine self-administration and high doses attenuating self-administration. Current studies show that bupropion facilitates the acquisition of nicotine conditioned place preference in rats, further suggesting that bupropion enhances the rewarding properties of nicotine. Bupropion has been shown to attenuate the expression of nicotine withdrawal symptoms in both animal models and human subjects. With respect to relapse, current studies show that bupropion attenuates nicotine-induced reinstatement in rats, but large individual differences are apparent. Clinically, bupropion is used as a treatment for two indications, as an antidepressant, the indication for which it was developed, and as a tobacco use cessation agent. In clinical trials, bupropion is being tested as a candidate treatment for psychostimulant drug abuse, attention-deficit hyperactivity disorder (ADHD) and obesity. Bupropion is available in three bioequivalent oral formulations, immediate release (IR), sustained release (SR), and extended release (XL). Extensive hepatic metabolism of bupropion produces three pharmacologically active metabolites, which may contribute to its clinical profile.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1527-3458.2006.00178.x

Cites

207 of 207 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635
The reinstatement model of drug relapse: history, methodology and major findings
Shaham, Y., Shalev, U., Lu, L., de Wit, H., & Stewart, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1224-x · Cited by 1,615
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361
Conditioned place preference: what does it add to our preclinical understanding of drug reward?
Bardo, M. T., & Bevins, R. A. (2000) · Psychopharmacology · doi:10.1007/s002130000569 · Cited by 1,274
Self-citation
A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710233371703 · Cited by 1,262
Smoking, smoking cessation, and major depression
Glassman, A. H. (1990) · JAMA · doi:10.1001/jama.1990.03450120058029 · Cited by 1,207
Drug Facts and Comparisons 1991.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-823_1 · Cited by 776
Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence
Volkow, N. D., Chang, L. L., Wang, G., Fowler, J. S., Franceschi, D., Sedler, M. J., Gatley, S. J., Miller, E. N., HITZEMANN, R. J., Ding, Y., et al. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09414.2001 · Cited by 754
Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
Wilson, J. M., Kalasinsky, K. S., Levey, A. I., Bergeron, C., Reiber, G. D., Anthony, R. M., Schmunk, G. A., Shannak, K. S., Haycock, J. W., & Kish, S. J. (1996) · Nature Medicine · doi:10.1038/nm0696-699 · Cited by 718
Methods of Assessing the Reinforcing Properties of Abused Drugs
Bozarth, M. A. (1987) · Springer eBooks · doi:10.1007/978-1-4612-4812-5 · Cited by 693
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Dramatic decreases in brain reward function during nicotine withdrawal
Epping-Jordan, M. P., Watkins, S. S., Koob, G. F., & Markou, A. (1998) · Nature · doi:10.1038/30001 · Cited by 674
Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602 · cited 1×
“In another line of work, bupropion has been shown to reduce methamphetamine-induced neurotoxicity in DA systems (104,107,153,183,196) and to decrease amphetamine self-administration in rats (139).”
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Bupropion is a nicotinic antagonist
Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38905-0 · Cited by 509
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
Jefferson, J. W., Pradko, J. F., & Muir, K. T. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.11.011 · Cited by 413
Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O’Brien, C. P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1423 · Cited by 405
Subunit Composition and Pharmacology of Two Classes of Striatal Presynaptic Nicotinic Acetylcholine Receptors Mediating Dopamine Release in Mice
Salminen, O., Murphy, K. L., McIntosh, J. M., Drago, J., Marks, M. J., Collins, A. C., & Grady, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1526 · Cited by 401
CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants
Hesse, L. M., Venkatakrishnan, K., Court, M. H., Moltke, L. L., Duan, S., Shader, R. I., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12046-9 · Cited by 398
Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys.
Bergman, J., Madras, B. K., Johnson, S. E., & Spealman, R. D. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20689-9 · Cited by 394
The Relationship Between Antidepressant Medication Use and Rate of Suicide
Gibbons, R. D., Hur, K., Bhaumik, D. K., & Mann, J. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.165 · Cited by 393
Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation: A Randomized, Controlled Trial
Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
α-Conotoxin AuIB Selectively Blocks α3β4 Nicotinic Acetylcholine Receptors and Nicotine-Evoked Norepinephrine Release
Luo, S., Kulak, J. M., Cartier, G. E., Jacobsen, R. B., Yoshikami, D., Olivera, B. M., & McIntosh, J. M. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-21-08571.1998 · Cited by 290
Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine
Fryer, J. D., & Lukas, R. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37928-5 · Cited by 283
Efficacy of antidepressants in substance use disorders with and without comorbid depression
Torrens, M., Fonseca, F., Mateu-Codina, G., & Farré, M. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.09.004 · Cited by 272
Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder
Hansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N., & Carey, T. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-6-200509200-00006 · Cited by 260
The effect of bupropion on nicotine craving and withdrawal
Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Gnys, M., Evoniuk, G., & DeVeaugh-Geiss, J. (2000) · Psychopharmacology · doi:10.1007/s002130050022 · Cited by 259
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors
Cryan, J. F., O’Leary, O. F., Jin, S., Friedland, J. C., Ouyang, M., Hirsch, B. R., Page, M. E., Dalvi, A., THOMAS, S. A., & Lucki, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401080101 · Cited by 256
Are there gender differences in smoking cessation, with and without bupropion? Pooled‐ and meta‐analyses of clinical trials of Bupropion SR
Scharf, D. M., & Shiffman, S. M. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00845.x · Cited by 255
Major depression following smoking cessation
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.2.263 · Cited by 250
Association of Dopamine Transporter Loss in the Orbitofrontal and Dorsolateral Prefrontal Cortices With Methamphetamine-Related Psychiatric Symptoms
Sekine, Y., Minabe, Y., Ouchi, Y., Takei, N., Iyo, M., Nakamura, K., Suzuki, K., Tsukada, H., Okada, H., Yoshikawa, E., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1699 · Cited by 242
Seizures and bupropion: a review.
Davidson, J. R. T. (1989) · PubMed · Cited by 234
Rewarding drugs produce taste avoidance, but not taste aversion
Parker, L. A. (1995) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(94)00028-y · Cited by 233
Blockade of Nicotine Self-Administration with Nicotinic Antagonists in Rats
Watkins, S. S., Epping-Jordan, M. P., Koob, G. F., & Markou, A. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00226-3 · Cited by 229
Conditioned taste aversions and drugs of abuse: A reinterpretation.
Grigson, P. S. (1997) · Behavioral Neuroscience · doi:10.1037/0735-7044.111.1.129 · Cited by 224
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat
Cryan, J. F., Bruijnzeel, A. W., Skjei, K. L., & Markou, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1445-7 · Cited by 223
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis.
Workman, E. A., & Short, D. D. (1993) · PubMed · Cited by 212
Treatment of bulimia with bupropion: a multicenter controlled trial.
Horne, R. L., Ferguson, J. M., Pope, H. G., Hudson, J. I., Lineberry, C. G., Ascher, J. A., & Cato, A. E. (1988) · PubMed · Cited by 212
Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors
Damaj, M. I., Carroll, F. I., Eaton, J. B., Navarro, H. A., Blough, B. E., Mirza, S., Lukas, R. J., & Martin, B. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001313 · Cited by 212
Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials
Lerman, C. E., Jepson, C., Wileyto, E. P., Epstein, L. H., Rukstalis, M. R., Patterson, F., Kaufmann, V., Restine, S., Hawk, L. W., NIAURA, R. S., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300861 · Cited by 197
Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study
Wilens, T. E., Haight, B. R., Horrigan, J. P., Hudziak, J. J., Rosenthal, N. E., Connor, D. F., Hampton, K. D., Richard, N. E., & Modell, J. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.027 · Cited by 193
Medication Development for Addictive Disorders: The State of the Science
Vocci, F. J., Acri, J. B., & Elkashef, A. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1432 · Cited by 192
Pharmacologic characterization of nicotine-induced conditioned place preference
Fudala, P. J., Teoh, K., & Iwamoto, E. T. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90384-3 · Cited by 190
Antidepressant-like effects in various mice strains in the forced swimming test
David, D. J. P., Renard, C. E., Jolliet, P., Hascoët, M., & Bourin, M. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1335-4 · Cited by 183
Evidence that the Acute Behavioral and Electrophysiological Effects of Bupropion (Wellbutrin®) Are Mediated by a Noradrenergic Mechanism
Cooper, B. R., Wang, C. M., Cox, R. F., Norton, R. M., Shea, V., & Ferris, R. M. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.43 · Cited by 183
Antidepressant-like effects in various mice strains in the tail suspension test
Ripoll, N., David, D. J. P., Dailly, É., Hascoët, M., & Bourin, M. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(03)00034-2 · Cited by 181
The Safety of Newer Antidepressants in Pregnancy and Breastfeeding
Gentile, S. (2005) · Drug Safety · doi:10.2165/00002018-200528020-00005 · Cited by 178
Bupropion
Holm, K. J., & Spencer, C. M. (2000) · Drugs · doi:10.2165/00003495-200059040-00019 · Cited by 175
Six-Month Trial of Bupropion With Contingency Management for Cocaine Dependence in a Methadone-Maintained Population
Poling, J. C., Oliveto, A. H., Petry, N. M., Sofuoglu, M., Gonsai, K., Gonzalez, G. M., Martell, B. A., & Kosten, T. R. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.219 · Cited by 168
A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients
Margolin, A., Kosten, T. R., Avants, S. K., Wilkins, J., Ling, W., Beckson, M., Arndt, I. O., Cornish, J., Ascher, J. A., Li, S.-H., et al. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01198-6 · Cited by 168
Release of dopamine via the human transporter.
Eshleman, A., Henningsen, R. A., Neve, K., & Janowsky, A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09929-8 · Cited by 168
Review of bupropion for smoking cessation
RICHMOND, R. L., & Zwar, N. A. (2003) · Drug and Alcohol Review · doi:10.1080/09595230100100642 · Cited by 167
Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving
Newton, T. F., Roache, J. D., Garza, R. D. L., FONG, T. W., Wallace, C. L., Li, S.-H., Elkashef, A. M., Chiang, N., & Kahn, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300979 · Cited by 163
Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study
Brody, A. L., Mandelkern, M. A., Lee, G., Smith, E. C., Sadeghi, M., Saxena, S., Jarvik, M. E., & London, E. D. (2004) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2003.12.006 · Cited by 158
Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.
Lerman, C. E., Shields, P. G., Wileyto, E. P., Audrain, J. E., Hawk, L. W., Pinto, A., Kucharski, S., Krishnan, S. S., NIAURA, R. S., & Epstein, L. H. (2003) · Health Psychology · doi:10.1037/0278-6133.22.5.541 · Cited by 156
Mediating mechanisms for the impact of bupropion in smoking cessation treatment
Lerman, C., Roth, D., Kaufmann, V., Audrain, J., Hawk, L., Liu, A., Niaura, R., & Epstein, L. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00067-4 · Cited by 155
A 102-center prospective study of seizure in association with bupropion.
Johnston, J. A., Lineberry, C. G., Ascher, J. A., Davidson, J. R. T., Khayrallah, M. A., Feighner, J. P., & Stark, P. (1991) · PubMed · Cited by 151
Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior.
Spealman, R. D., Madras, B. K., & Bergman, J. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20686-3 · Cited by 150
Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats
Bruijnzeel, A. W., & Markou, A. (2003) · Synapse · doi:10.1002/syn.10242 · Cited by 146
Inhibition of CYP2D6 Activity by Bupropion
Kotlyar, M., Brauer, L. H., Tracy, T. S., Hatsukami, D. K., Harris, J., Bronars, C. A., & Adson, D. E. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162805.46453.e3 · Cited by 144
A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation
Tønnesen, P., Tonstad, S., Hjalmarson, Å., Lebargy, F., van Spiegel, P. I., Hider, A., Sweet, R., & Townsend, J. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01185.x · Cited by 143
Intravenous Self-Administration: Response Rates, the Effects of Pharmacological Challenges, and Drug Preference
Yokel, R. A. (1987) · Springer eBooks · doi:10.1007/978-1-4612-4812-5_1 · Cited by 143
Use of Bupropion in Combination with Serotonin Reuptake Inhibitors
Zisook, S., Rush, A. J., Haight, B. R., Clines, D. C., & Rockett, C. B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.027 · Cited by 140
Bupropion and amitriptyline in the treatment of depressed patients.
Lader, M. (1983) · PubMed · Cited by 140
Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers
Hsyu, P., Singh, A. K., Giargiari, T. D., Dunn, J. A., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04361.x · Cited by 137
Characterization of nicotinic receptors involved in the release of noradrenaline from the hippocampus
Sershen, H. W., Balla, A., Lajtha, Á., & Vizi, E. S. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00425-3 · Cited by 136
Studies of bupropion's mechanism of antidepressant activity.
Ferris, R. M., Cooper, B. R., & Maxwell, R. A. (1983) · PubMed · Cited by 127
Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons
Marek, G. J., Vosmer, G. L., & Seiden, L. S. (1990) · Brain Research · doi:10.1016/0006-8993(90)90467-p · Cited by 124
Who gets what symptom? Effects of psychiatric cofactors and nicotine dependence on patterns of smoking withdrawal symptomatology
Pomerleau, J. L. M. C. S. (2000) · Nicotine & Tobacco Research · doi:10.1080/14622200050147547 · Cited by 123
Bupropion overdose: A 3-year multi-center retrospective analysis
Spiller, H. A., Ramoska, E. A., Krenzelok, E. P., et al. (1994) · The American Journal of Emergency Medicine · doi:10.1016/0735-6757(94)90195-3 · Cited by 122
Bupropion in Depression
Golden, R. N. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800260055007 · Cited by 122
Metabolism and kinetics of bupropion.
Dh, S. (1983) · PubMed · Cited by 121
Antidepressants and seizures: emphasis on newer agents and clinical implications
Montgomery, S. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00731.x · Cited by 119
How does bupropion work as a smoking cessation aid?
Warner, C., & Shoaib, M. (2005) · Addiction Biology · doi:10.1080/13556210500222670 · Cited by 115
Effect of bupropion on nicotine self-administration in rats
Rauhut, A. S., Neugebauer‎, N. M., Dwoskin, L. P., & Bardo, M. T. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1450-x · Cited by 112
Self-citation
Acute doses of d-amphetamine and bupropion increase cigarette smoking
Cousins, M. S., Stamat, H. M., & de Wit, H. (2001) · Psychopharmacology · doi:10.1007/s002130100802 · Cited by 109
The effect of bupropion sustained-release on cigarette craving after smoking cessation
Durcan, M. J., Deener, G., White, J., Johnston, J. A., Gonzales, D. H., NIAURA, R. S., Rigotti, N. A., & Sachs, D. P. L. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85130-x · Cited by 109
Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum.
Nomikos, G. G., Damsma, G., Wenkstern, D., & Fibiger, H. C. (1992) · PubMed · Cited by 109
Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans.
Rush, C. R., Kollins, S. H., & Pazzaglia, P. J. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.6.1.32 · Cited by 108
Recognizing and treating depression in children and adolescents
Dopheide, J. A. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050264 · Cited by 108
SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRO
Turpeinen, M., Nieminen, R. M., Juntunen, T., Taavitsainen, P., Raunio, H., & Pelkonen, O. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.626 · Cited by 108
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner, J. P., Gardner, E. A., Johnston, J. A., Batey, S. R., Khayrallah, M. A., Ascher, J. A., & Lineberry, C. G. (1991) · PubMed · Cited by 107
Comparison of Bupropion and Trazodone for the Treatment of Major Depression
Weisler, R. H., Johnston, J., Lineberry, C. G., Samara, B., Branconnier, R. J., & Billow, A. A. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199406000-00004 · Cited by 107
Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department
Pesola, G. R., & Avasarala, J. (2002) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(01)00474-7 · Cited by 105
Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects
Findlay, J. W. A., Fleet, J. V. W., Smith, P., et al. (1981) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637513 · Cited by 105
Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity
Loboz, K. K., Gross, A. S., WILLIAMS, K., Liauw, W., Day, R. O., Blievernicht, J., Zanger, U. M., & McLachlan, A. J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.010 · Cited by 98
A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future
Taylor, W. D., & Doraiswamy, P. M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300550 · Cited by 96
National patterns of medication treatment for depression, 1987 to 2001
Stafford, R. S., MacDonald, E. A., & Finkelstein, S. N. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0611 · Cited by 94
TOBACCO CESSATION AMONG PATIENTS WITH DEPRESSION
Covey, L. S. (1999) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(05)70124-x · Cited by 93
Modulation of nicotine self-administration in rats by combination therapy with agents blocking α3β4 nicotinic receptors
Glick, S. D., Maisonneuve, I. M., & Kitchen, B. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01944-1 · Cited by 92
Excretion of Bupropion in Breast Milk
BRIGGS, G. G., Samson, J. H., Ambrose, P. J., & Schroeder, D. H. (1993) · Annals of Pharmacotherapy · doi:10.1177/106002809302700406 · Cited by 92
Characteristics of conditioned taste aversion produced by nicotine in rats
Kumar, R., Pratt, J. A., & Stolerman, I. P. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb10518.x · Cited by 91
Behavioral and biochemical investigations of bupropion metabolites
Bondarev, M. L., Bondareva, T. S., Young, R., & Glennon, R. A. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02010-7 · Cited by 89
Nicotine as a signal for the presence or absence of sucrose reward: a Pavlovian drug appetitive conditioning preparation in rats
Besheer, J., Palmatier, M. I., Metschke, D. M., & Bevins, R. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1621-9 · Cited by 89
Bupropion exposures: clinical manifestations and medical outcome
Belson, M. G., & Kelley, T. R. (2002) · Journal of Emergency Medicine · doi:10.1016/s0736-4679(02)00522-x · Cited by 88
Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs.
Suckow, R. F., Smith, T. M., Perumal, A. S., & Cooper, T. B. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08996-2 · Cited by 85
Investigating the actions of bupropion on dependence-related effects of nicotine in rats
Shoaib, M. C., Sidhpura, N., & Shafait, S. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1277-x · Cited by 84
Addressing women's concerns about weight gain due to smoking cessation
Perkins, K. A. (1997) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(96)00158-4 · Cited by 84
The discriminative stimulus effects of cocaine in pigeons.
Johanson, C. E., & Barrett, J. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39359-6 · Cited by 84
Bupropion Inhibits Nicotine-Evoked [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine and from Rat Hippocampal Slices Preloaded with [3H]Norepinephrine
Miller, D. K., Sumithran, S. P., & Dwoskin, L. P. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033852 · Cited by 84
Self-citation
Behavioral screen for antidepressants: The effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule
Seiden, L. S., Dahms, J. L., & Shaughnessy, R. A. (1985) · Psychopharmacology · doi:10.1007/bf00431684 · Cited by 83
Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression
Cox, L. S., Patten, C. A., NIAURA, R. S., Decker, P. A., Rigotti, N. A., Sachs, D. P. L., Buist, A. S., & Hurt, R. D. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30423.x · Cited by 82
Bupropion SR for the treatment of postpartum depression: a pilot study
Nonacs, R. M., Soares, C. N., Viguera, A. C., Pearson, K. H., Poitras, J. R., & Cohen, L. S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005079 · Cited by 82
Treatment of Anxiety and Depression in Transplant Patients
Crone, C. C., & Gabriel, G. M. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443060-00002 · Cited by 81
Pharmacological significance of the species differences in bupropion metabolism
Welch, R. M., Lai, A. A., & Schroeder, D. H. (1987) · Xenobiotica · doi:10.3109/00498258709043939 · Cited by 80
Determination of Bupropion and Its Major Basic Metabolites in Plasma by Liquid Chromatography With Dual-Wavelength Ultraviolet Detection
Cooperx, T. B., Suckow, R. F., & Glassman, A. H. (1984) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600730820 · Cited by 79
Bupropion: A new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β-adrenergic, serotonergic (5-HT2), α2-adrenergic, imipramine and dopaminergic receptors in brain
Ferris, R. M. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90198-3 · Cited by 79
Bupropion poisoning: a case series
Balit, C. R., Lynch, C. N., & Isbister, G. K. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05064.x · Cited by 79
Bupropion sustained release and smoking cessation.
Goldstein, M. G. (1998) · PubMed · Cited by 78
Differential Regulation of Dopamine Transporter after Chronic Self-administration of Bupropion and Nomifensine
Tella, S. R., Ladenheim, B., & Cadet, J. L. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36624-8 · Cited by 76
Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose
Laizure, S. C., DeVane, C. L., Stewart, J. T., et al. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.228 · Cited by 76
The cognitive neuropsychology of attention: A frontal lobe perspective
Foster, J. K., Eskes, G. A., & Stuss, D. T. (1994) · Cognitive Neuropsychology · doi:10.1080/02643299408251971 · Cited by 75
HPLC assay for bupropion and its major metabolites in human plasma
Loboz, K. K., Gross, A. S., Ray, J. E., et al. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.06.009 · Cited by 75
Bupropion: clinical assay for amphetamine-like abuse potential.
Griffith, J. D., Carranza, J., Griffith, C., & Miller, L. L. (1983) · PubMed · Cited by 75
Pharmacokinetics of Single‐ and Multiple‐Dose Bupropion in Elderly Patients with Depression
Sweet, R. A., Pollock, B. G., Kirshner, M. A., et al. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04132.x · Cited by 72
A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients
Reimherr, F. W., Cunningham, L. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80060-x · Cited by 72
Bupropion increases striatal vesicular monoamine transport
Rau, K. S., Birdsall, E., Hanson, J. E., Johnson‐Davis, K. L., Carroll, F. I., Wilkins, D. G., Gibb, J. W., Hanson, G. R., & Fleckenstein, A. E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.05.004 · Cited by 72
Antidepressant Profile of Bupropion and three Metabolites in Mice
Martin, P., Massol, J., Colin, J. N., Lacomblez, L., & Puech, A. J. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014505 · Cited by 71
Stimulus properties of antidepressants in the rat
Jones, C. N., Howard, J. L., & McBennett, S. T. (1980) · Psychopharmacology · doi:10.1007/bf00431964 · Cited by 71
Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine
Lamb, R. J., & Griffiths, R. R. (1990) · Psychopharmacology · doi:10.1007/bf02245920 · Cited by 70
Nicotine and bupropion share a similar discriminative stimulus effect
Young, R., & Glennon, R. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01554-6 · Cited by 69
Reboxetine: Attenuation of Intravenous Nicotine Self-Administration in Rats
Rauhut, A. S., Mullins‐Sweatt, S. N., Dwoskin, L. P., & Bardo, M. T. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.303.2.664 · Cited by 67
Self-citation
Bupropion attenuates nicotine abstinence syndrome in the rat
Malin, D. H., Lake, J. R., Smith, T. D., Khambati, H. N., Meyers-Paal, R. L., Montellano, A. L., Jennings, R. E., Erwin, D. S., Presley, S. E., & Perales, B. A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0135-z · Cited by 67
Bupropion and Breastfeeding: A Case of a Possible Infant Seizure
Chaudron, L. H., & Schoenecker, C. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0622f · Cited by 67
Effects of Antidepressant Drugs on Rats Bred for Low Activity in the Swim Test
West, C. H. K., & Weiss, J. M. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00076-8 · Cited by 66
Fatal Bupropion Overdose
Harris, C. R., Gualtieri, J. F., & Stark, G. (1997) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563659709001220 · Cited by 66
Bupropion for the treatment of nicotine withdrawal and craving
Mooney, M. E., & Sofuoglu, M. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.7.965 · Cited by 65
Pharmacological characterization of the discriminative-stimulus effects of GBR 12909.
Melia, K. F., & Spealman, R. D. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20292-0 · Cited by 64
A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine
Heal, D. J., Frankland, A. T. J., Gosden, J., et al. (1992) · Psychopharmacology · doi:10.1007/bf02245152 · Cited by 63
A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees
Dalsgarð, Ó. J., Hansen, N.-C. G., Søes‐Petersen, U., Evald, T., Høegholm, A., Barber, J., & Vestbo, J. (2004) · Nicotine & Tobacco Research · doi:10.1080/14622200310001656867 · Cited by 63
Dopaminergic involvement in the discriminative-stimulus effects of methamphetamine in rats
Munzar, P., & Goldberg, S. R. (2000) · Psychopharmacology · doi:10.1007/s002130050044 · Cited by 63
Animal model of depression: Tests of three structurally and pharmacologically novel antidepressant compounds
Katz, R. J., & Sibel, M. (1982) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(82)90055-7 · Cited by 61
Reboxetine: Functional Inhibition of Monoamine Transporters and Nicotinic Acetylcholine Receptors
Miller, D. K., Wong, E. H. F., Chesnut, M. D., & Dwoskin, L. P. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.687 · Cited by 60
Self-citation
Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects
Katz, J. L., Izenwasser, S., & Terry, P. (2000) · Psychopharmacology · doi:10.1007/s002130050029 · Cited by 59
Bupropion Overdose: QTc Prolongation and its Clinical Significance
Isbister, G. K., & Balit, C. R. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c481 · Cited by 59
The existence of tolerance to and cross-tolerance between d-amphetamine and methylphenidate for their effects on milk consumption and on differential-reinforcement-of-low-rate performance in the rat.
Pearl, R. G., & Seiden, L. S. (1976) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30636-1 · Cited by 55
Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.
Faucette, S. R., Hawke, R. L., Shord, S. S., et al. (2001) · PubMed · Cited by 55
Enantiomeric Determination of the Phenylmorpholinol Metabolite of Bupropion in Human Plasma Using Coupled Achiral-Chiral Liquid Chromatography
Suckow, R. F., Zhang, M. F., & Cooper, T. B. (1997) · Biomedical Chromatography · doi:10.1002/(sici)1099-0801(199705)11:3 · Cited by 53
Nicotine-like discriminative stimulus effects of bupropion in rats.
Wiley, J. L., LaVecchia, K. L., Martin, B. R., & Damaj, M. I. (2002) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.10.2.129 · Cited by 52
Autophonia associated with an atypical eating disorder.
Fleet, J. V. W., Manberg, P. J., Miller, L. L., et al. (1983) · PubMed · Cited by 51
Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment
Dong, J.-M., & Blier, P. (2001) · Psychopharmacology · doi:10.1007/s002130000665 · Cited by 48
Combining Stimulants With Monoamine Oxidase Inhibitors
Feinberg, S. S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1113 · Cited by 48
The discriminative stimulus effects of methamphetamine in pigeons
Sasaki, J. E., Tatham, T. A., & Barrett, J. (1995) · Psychopharmacology · doi:10.1007/bf02311178 · Cited by 48
Nicotine-like discriminative stimulus effects of bupropion in rats.
Wiley, J. L., LaVecchia, K. L., Martin, B. R., et al. (2002) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.10.2.129 · Cited by 47
Antagonism of stimulus properties of nicotine by dihydro-β-erythroidine (DHβE) in rats
Shoaib, M., Zúbaran, C., & Stolerman, I. P. (2000) · Psychopharmacology · doi:10.1007/s002139900348 · Cited by 46
Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion
Wileyto, E. P., Patterson, F., NIAURA, R. S., Epstein, L. H., Brown, R. A., Audrain-McGovern, J. E., Hawk, L. W., & Lerman, C. E. (2005) · Nicotine & Tobacco Research · doi:10.1080/14622200500055673 · Cited by 46
Pharmacokinetics of Bupropion and Its Metabolites in Haemodialysis Patients Who Smoke
Worrall, S. P. R., Almond, M. K., & Dhillon, S. (2004) · Nephron Clinical Practice · doi:10.1159/000078635 · Cited by 46
Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons
Nielsen, J. A., Shannon, N., Bero, L. A., & Moore, K. E. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90413-2 · Cited by 45
Population pharmacokinetic analysis of drug–drug interactions among risperidone, bupropion, and sertraline in CF1 mice
Wang, J.-S., DeVane, C. L., Gibson, B. B., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0209-y · Cited by 45
Change From the CYP2D6 Extensive Metabolizer to the Poor Metabolizer Phenotype During Treatment With Bupropion
Güzey, C., Norström, Å., & Spigset, O. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200206000-00018 · Cited by 44
Steady-State Pharmacokinetics of Bupropion SR in Juvenile Patients
Daviss, W. B., Perel, J. M., Rudolph, G. R., Axelson, D., Gilchrist, R., Nuss, S., Birmaher, B. B., & Brent, D. A. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000153225.26850.26 · Cited by 44
Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response
Ott, G. E., Rao, U., Lin, K., Gertsik, L., & Poland, R. E. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004298 · Cited by 44
A double-blind study of alprazolam and lorazepam in the treatment of anxiety.
Ruiz, A. S. (1983) · PubMed · Cited by 43
Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats
Terry, P., & Katz, J. L. (1997) · Psychopharmacology · doi:10.1007/s002130050443 · Cited by 43
Adverse Effects Associated with Extra Doses of Bupropion
Shepherd, G. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.10.1378 · Cited by 42
Bupropion Plasma Levels and CYP2D6 Phenotype
Pollock, B. G., Sweet, R. A., Kirshner, M., et al. (1996) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199610000-00010 · Cited by 42
Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients
Straneva, P. A. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00352-x · Cited by 42
Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion
Musso, D. L., Mehta, N. B., Soroko, F. E., et al. (1993) · Chirality · doi:10.1002/chir.530050704 · Cited by 40
Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Organic mental disorders associated with bupropion in three patients.
Ames, D., Wirshing, W. C., & Szuba, M. P. (1992) · PubMed · Cited by 40
Anorectic and behavioural effects of bupropion
Zarrindast, M. R., & Hosseini-Nia, T. (1988) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(88)90061-4 · Cited by 39
Perceptual changes with bupropion, a novel antidepressant
Becker, R. E., & Dufresne, R. L. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1200 · Cited by 39
The conditioned place preference paradigm in rats: Effect of bupropion
Ortmann, R. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90033-5 · Cited by 38
Characterization of nicotine's ability to serve as a negative feature in a Pavlovian appetitive conditioning task in rats
Bevins, R. A., Wilkinson, J. L., Palmatier, M. I., Siebert, H. L., & Wiltgen, S. M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0079-3 · Cited by 38
Bupropion-induced convulsions: Preclinical evaluation of antiepileptic drugs
Tutka, P., Mróz, T., Klucha, K., Piekarczyk, M., & Wielosz, M. (2005) · Epilepsy Research · doi:10.1016/j.eplepsyres.2005.01.006 · Cited by 37
Discriminative Stimulus Effects of a Cocaine/Heroin “Speedball” Combination in Rhesus Monkeys
Negus, S. S., Gatch, M. B., & Mello, N. K. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37510-x · Cited by 37
Antagonism of the behavioral effects of cocaine and d-amphetamine by prazosin
Tessel, R. E., & Barrett, J. (1986) · Psychopharmacology · doi:10.1007/bf00174057 · Cited by 36
The cardiovascular profile of bupropion.
Wenger, T. L., & Stern, W. C. (1983) · PubMed · Cited by 35
Recreational bupropion abuse in a teenager
McCormick, J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01538.x · Cited by 34
Bupropion slow-release response in depression: diagnosis and biochemistry
Goodnick, P. J., Dominguez, R., DeVane, C. L., & Bowden, C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00520-9 · Cited by 34
Nicotinic receptors modulating somatodendritic and terminal dopamine release differ pharmacologically
Reuben, M., Boye, S., & Clarke, P. B. S. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00004-2 · Cited by 33
Tolerance does not develop to the decrease in nicotine self‐administration produced by repeated bupropion administration
Rauhut, A. S., Dwoskin, L. P., & Bardo, M. T. (2005) · Nicotine & Tobacco Research · doi:10.1080/14622200500381384 · Cited by 32
Self-citation
Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: Preliminary evidence for different binding domains
Dersch, C. M., Akunne, H. C., Partilla, J. S., et al. (1994) · Neurochemical Research · doi:10.1007/bf00966817 · Cited by 31
Bupropion: risks and benefits
Ross, S., & Williams, D. J. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.995 · Cited by 31
Subjective Effects of Slow-Release Bupropion versus Caffeine as Determined in a Quasi-Naturalistic Setting
Zernig, G., de Wit, H., Telser, S., et al. (2004) · Pharmacology · doi:10.1159/000075550 · Cited by 30
Bupropion Insufflation in a Teenager
Khurshid, K. A., & Decker, D. H. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454604773840634 · Cited by 29
Inhibition of nicotine-induced hippocampal norepinephrine release in rats by alpha-conotoxins MII and AuIB microinjected into the locus coeruleus
Fu, Y., Matta, S. G., McIntosh, J. M., & Sharp, B. M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00293-1 · Cited by 28
Desipramine-associated SIADH in an elderly woman: case report.
Othmer, E., Othmer, S. C., Stern, W. C., & Fleet, J. V. W. (1983) · PubMed · Cited by 27
Characterization of the bupropion cue in the rat: Lack of evidence for a dopaminergic mechanism
Blitzer, R. D., & Becker, R. E. (1985) · Psychopharmacology · doi:10.1007/bf00428409 · Cited by 27
Acute Antidepressant Response and Plasma Levels of Bupropion and Metabolites in a Pediatric-Aged Sample
Daviss, W. B., Perel, J. M., Brent, D. A., et al. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000197093.92559.7a · Cited by 27
Bupropion effects on aggressiveness and anxiety in OF1 male mice
Redolat, R., G�mez, M. C., Vicens, P., & Carrasco, M. C. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1965-9 · Cited by 27
Bupropion overdose in an adolescent
Ayers, S., & Tobias, J. D. (2001) · Pediatric Emergency Care · doi:10.1097/00006565-200104000-00006 · Cited by 26
The effects of long-term administration of antidepressant drugs on intracranial self-stimulation responding in rats
McCarter, B. D., & Kokkinidis, L. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90341-3 · Cited by 25
Bupropion (Zyban) toxicity.
Tracey, J., Cassidy, N., Casey, P. B., & Ali, I. (2002) · PubMed · Cited by 25
Catatonia associated with bupropion treatment.
Jackson, C. W., Head, L. A., & Kellner, C. H. (1992) · PubMed · Cited by 25
Sustained release bupropion overdose: an important cause of prolonged symptoms after an overdose
Jepsen, F. (2003) · Emergency Medicine Journal · doi:10.1136/emj.20.6.560 · Cited by 24
Role of D-1 and D-2 receptors in apomorphine-induced pecking in chicks
Zarrindast, M., & Amin, R. (1992) · Psychopharmacology · doi:10.1007/bf02253590 · Cited by 23
Cytochrome P450 2D6 polymorphism and character traits
Suzuki, E., Kitao, Y., Ono, Y., et al. (2003) · Psychiatric Genetics · doi:10.1097/01.ypg.0000056175.32550.37 · Cited by 23
Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice
Carrasco, M. C., Vicens, P., Vidal, J., & Redolat, R. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.06.005 · Cited by 21
Chronic antidepressant and clonidine treatment effects on conflict behavior in the rat
Commissaris, R. L., Ellis, D. M., Hill, T. J., Schefke, D. M., Becker, C. A., & Fontana, D. J. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90058-p · Cited by 21
Acute psychosis following sustained release bupropion overdose
Wang, T., Shiah, I., Yeh, C., et al. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.10.003 · Cited by 21
Effects of bupropion on core body temperature of mice
Zarrindast, M., & Abolfathi-Araghi, F. (1992) · Psychopharmacology · doi:10.1007/bf02801980 · Cited by 21
Effects of co-administration of bupropion and nicotinic agonists on the elevated plus-maze test in mice
Carrasco, M. C., Vicens, P., Vidal, J., & Redolat, R. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.018 · Cited by 20
Bupropion induces sniffing: A possible dopaminergic mechanism
Zarrindast, M. R., Hojjati, M. R., Pejhan, A., et al. (1996) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00034-x · Cited by 20
Preexposure to nicotine alters the subsequent locomotor stimulant effects of bupropion in rats
Wilkinson, J. L., Palmatier, M. I., & Bevins, R. A. (2006) · Nicotine & Tobacco Research · doi:10.1080/14622200500484642 · Cited by 20
Effects of dopamine uptake inhibitors on schedule-controlled behavior in the squirrel monkey
McKearney, J. W. (1982) · Psychopharmacology · doi:10.1007/bf00433746 · Cited by 20
Relationship between bupropion disposition and dopamine uptake inhibition in rats and mice.
Butz, R. F., Welch, R. M., & Findlay, J. W. A. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33118-6 · Cited by 20
Bupropion Hydrochloride
Dufresne, R. L., Weber, S. S., & Becker, R. E. (1984) · Annals of Pharmacotherapy · doi:10.1177/106002808401801201 · Cited by 19

Flagged first, then by citations

Research works printed but not linked: 6

Ferry LH, 1994, Bupropion for smoking cessation in non‐depressed smokers, J Addict Dis, 13, 249
Fiore MC, 2000, Treating tobacco use and dependence: Quick reference guide for clinicians
10.1345/aph.1A099 · DOI · Paper page
Othmer E, 1983, Long‐term efficacy and safety of bupropion, J Clin Psychiatry, 44, 153
Tucker WE, 1983, Preclinical toxicology of bupropion: An overview, J Clin Psychiatry, 44, 60
Van Wyck Fleet J, 1983, Overview of clinically significant adverse reactions to bupropion, J Clin Psychiatry, 44, 191

Sorted by citations

Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
REVIEW ON CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade
Tzschentke, T. M. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00070.x · Cited by 1,336
Cellular bioenergetics as a target for obesity therapy
Tseng, Y.-H., Cypess, A. M., & Kahn, C. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3138 · Cited by 591
It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood
PICCIOTTO, M., ADDY, N., MINEUR, Y., & BRUNZELL, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.005 · Cited by 460
Making a bad thing worse: adverse effects of stress on drug addiction
Cleck, J. N., & Blendy, J. A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33946 · Cited by 122

See all 259

Authors: Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T.
Affiliations: University of Kentucky (US)
Dickinson College (US)
Corresponding author: Dwoskin, Linda P.
ORCID: Rauhut, Anthony S.
Bardo, Michael T.
Venue: CNS Drug Reviews
Publisher: Wiley
Published: 2006-09
Volume: 12
Issue: 3-4
Pages: 178-207
ISSN: 1080-563X (ISSN-L)
1527-3458
DOI: 10.1111/j.1527-3458.2006.00178.x
PMC: PMC6506196
OpenAlex: W2067382805
Cited by: 259
References: 207
Citations by year: 2026: 8 · 2025: 9 · 2024: 5 · 2023: 2 · 2022: 12 · 2021: 14 · 2020: 12 · 2019: 10 · 2018: 13 · 2017: 12 · 2016: 21 · 2015: 11 · 2014: 22 · 2013: 18 · 2012: 13
FWCI: 1.71
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 132 d)
Locations: CNS Drug Reviews (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (DA07304, DA-05312)
National Institute on Drug Abuse (DA 017548, DA 07304, DA018372, U19DA017548, DA05312, R21DA018372)
National Institute of Environmental Health Sciences (T32ES007266, ES 07266)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: bupropion, antidepressants, tobacco cessation, nicotine self-administration, nicotine withdrawal, dopamine transporter inhibition, norepinephrine reuptake inhibition, nicotinic acetylcholine receptor antagonism, attention deficit hyperactivity disorder, obesity, hepatic metabolism, pharmacokinetics, sustained-release formulation
MeSH terms: Animals, Humans, Tobacco Use Disorder, Bupropion, Antidepressive Agents, Second-Generation, Tobacco Use Cessation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks